Provided by Tiger Trade Technology Pte. Ltd.

Amneal Pharmaceuticals, Inc.

17.78
-0.1300-0.73%
Post-market: 17.77-0.0100-0.06%19:30 EDT
Volume:1.79M
Turnover:31.81M
Market Cap:5.67B
PE:36.98
High:17.92
Open:17.81
Low:17.61
Close:17.91
52wk High:19.26
52wk Low:9.20
Shares:319.00M
Float Shares:182.33M
Volume Ratio:1.16
T/O Rate:0.98%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.4808
EPS(LYR):0.2200
ROE:613.02%
ROA:8.60%
PB:171.75
PE(LYR):80.82

Loading ...

Amneal EVP, Chief Legal Officer Jason B. Daly Sells USD 3.77 Million in Common Shares

Reuters
·
Aug 14

Amneal Completes Acquisition of Kashiv BioSciences

Reuters
·
Aug 10

Amneal Completes Acquisition of Kashiv Biosciences, Creating a Global Biosimilar Leader

THOMSON REUTERS
·
Aug 10

Amneal Pharmaceuticals' (NASDAQ:AMRX) Strong Earnings Are Of Good Quality

Simply Wall St.
·
Aug 07

Amneal Pharmaceuticals - Converts Term Loans to $2.04 Bln; Incurs New $45.20 Mln Term Loan - SEC Filing

THOMSON REUTERS
·
Aug 04

Amneal Reprices Term Loan, Cuts Interest Margin 50 Bps on USD 2.08 Billion Facility

Reuters
·
Aug 04

Amneal Pharmaceuticals is Maintained at Buy by UBS

Dow Jones
·
Aug 04

Amneal Pharmaceuticals Has Favorable Setup for Growth With Product Approvals, Launches, UBS Says

MT Newswires Live
·
Aug 04

UBS Adjusts Price Target on Amneal Pharmaceuticals to $25 From $23, Maintains Buy Rating

MT Newswires Live
·
Aug 03

Did Strong Q2 Results and Higher 2026 Revenue Guidance Just Shift Amneal Pharmaceuticals' (AMRX) Investment Narrative?

Simply Wall St.
·
Aug 03

Amneal Pharmaceuticals Held Special Shareholder Meeting on Kashiv BioSciences Deal

Reuters
·
Aug 01

Amneal Pharmaceuticals Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Jul 31

U.S. Stocks on the MOVE-Mastercard, Starbucks, Meta

Reuters
·
Jul 30

Stock Track | Amneal Pharmaceuticals Plummets 6.39% as Tepid Guidance Overshadows Q2 Beat

Stock Track
·
Jul 30

Amneal Gains After Slightly Lifting Full-year Forecast, Q2 Beat

Reuters
·
Jul 30

Stock Track | Amneal Pharmaceuticals Soars 9.95% in Pre-market After Q2 Earnings Beat and Raised Guidance

Stock Track
·
Jul 30

Amneal Q2 Revenue Beats on Specialty Segment Growth

Reuters
·
Jul 30

GUIDANCE: (AMRX) Amneal Pharmaceuticals Expects Full Year 2026 Revenue Range $3.10B - $3.20B, vs. FactSet Est of $3.11B

MT Newswires Live
·
Jul 30

Amneal Q2 FY26 GAAP Net Income More than Doubles to $58 Million; Revenue Rises 10% to $796 Million

Reuters
·
Jul 30

Amneal Pharmaceuticals Shares up 10.5% Premarket After Q2 Profit Beat

THOMSON REUTERS
·
Jul 30